NATCO Pharma Limited (NSE:NATCOPHARM)
1,034.20
+31.50 (3.14%)
Mar 10, 2026, 1:50 PM IST
NATCO Pharma Revenue
NATCO Pharma had revenue of 6.47B INR in the quarter ending December 31, 2025, with 36.33% growth. This brings the company's revenue in the last twelve months to 45.63B, up 6.60% year-over-year. In the fiscal year ending March 31, 2025, NATCO Pharma had annual revenue of 44.32B with 10.74% growth.
Revenue (ttm)
45.63B
Revenue Growth
+6.60%
P/S Ratio
3.94
Revenue / Employee
10.87M
Employees
4,199
Market Cap
179.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 44.32B | 4.30B | 10.74% |
| Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
| Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
| Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
| Mar 31, 2021 | 20.56B | 1.41B | 7.37% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ipca Laboratories | 95.06B |
| Piramal Pharma | 88.71B |
| Emcure Pharmaceuticals | 88.50B |
| Alembic Pharmaceuticals | 72.67B |
| Gland Pharma | 61.13B |
| Ajanta Pharma | 52.02B |
| Strides Pharma Science | 47.26B |
| Wockhardt | 31.74B |
NATCO Pharma News
- 4 days ago - Pharma sector stocks today, March 6: Shilpa Medicare surge 3.08%, Wockhardt jumps 2.12%, Natco Pharma up 1.84%, - Business Upturn
- 5 days ago - Pharma sector stocks surge today, March 5: Natco Pharma jumps 3.35%, Granules India up 2.74%, Alembic surge nearly 2% - Business Upturn
- 6 days ago - Natco Pharma shares rise over 2% after launch of generic Pomalidomide Capsules in the US - Business Upturn
- 7 days ago - Natco Pharma launches Generic Pomalidomide Capsules in US market - Business Upturn
- 8 days ago - Pharma sector stocks down today, March 2: Morepen Lab falls 3.24%, Ajanta Pharma drops 2.32%, Natco Pharma down 2.26% - Business Upturn
- 11 days ago - Pharma sector stocks today, Feb 27: Dr. Reddys Lab down 1.14%, Cipla falls 1.04%, Natco Pharma up 1.09% - Business Upturn
- 13 days ago - NATCO Pharma clarifies on Semaglutide launch plans; says no material impact from Eris partnership news - Business Upturn
- 14 days ago - Eris Lifesciences partners with Natco Pharma to launch Semaglutide in India - Business Upturn